Title
Endogenous cannabinoids and their neurobiological and functional role in schizophrenia spectrum disorders

Permalink
https://escholarship.org/uc/item/1345w4w8

Journal
BIOLOGICAL PSYCHIATRY, 55

ISSN
0006-3223

Authors
Leweke, FM
Giuffrida, A
Gerth, CW
et al.

Publication Date
2004-04-15

License
https://creativecommons.org/licenses/by/4.0/ 4.0

Peer reviewed
371. Endogenous Cannabinoids and Their Neurobiological and Functional Role in Schizophrenia Spectrum Disorders

F. Markus Leweke1, Andrea Giuffrida2, Christoph W. Gerth1, Dagmar Koethe1, Daniela Schreiber1,3, Joachim Klosterkötter1, Daniele Piomelli3

1Dept. of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany, 2Dept. of Pharmacology, University of Texas Health Science Center, San Antonio, TX, 3Dept. of Pharmacology, University of California, Irvine, Irvine, CA

Background: Activation of cannabinoid CB1 receptors produces intense emotional and cognitive responses, suggesting that dysfunction in the endocannabinoid system may contribute to the pathogenesis of mental disorders.

Methods: We have examined the role of endocannabinoid signaling in psychotic states by measuring levels of the endocannabinoid anandamide in cerebrospinal fluid (CSF) and serum of various groups of healthy volunteers (n=84) and patients suffering from acute psychiatric disorders (n=187) by HPLC/MS.

Results: The level of anandamide in CSF is significantly elevated in acute, antipsychotic-naive, first-episode schizophrenic patients (n=47) when compared
to controls. This is reversed by the administration of antipsychotics, which antagonize dopamine D2-like receptors (n=37), but not by those, which preferentially antagonize 5HT2A receptors (n=34). Furthermore, we found that, in antipsychotic-naïve, acute schizophrenics, CSF anandamide is negatively correlated with psychotic symptoms. Our findings were specific for schizophrenia spectrum disorders.

Conclusions: Our results suggest that anandamide elevation in schizophrenia may reflect a compensatory adaptation to dopaminergic hyperactivity revealing an unexpected protective role for this endocannabinoid lipid in psychotic states.